Citations

Clear

371 citation(s) found for "Cho, B".

Changes in Obesity Prevalence Among U.S. Adults After the COVID-19 Pandemic by State and Territorial Stay-at-Home Order Level and Sociodemographic Characteristics
Cho, Beomyoung , Pan, Yining , Chapman, McKinley , Spaulding, Aaron , Stallings‐Smith, Sericea , Spaulding, Aaron

Mayo Clinic

American Journal of Health Promotion | February 12, 2024 | Volume: 38 | Issue: 6 | Pages: 787-796

10.1177/08901171241233399 | PMID 38345895 Get It

Purpose To examine changes in obesity prevalence among US adults after the COVID-19 pandemic by level of stay-at-home order and sociodemographic characteristics. Design Quasi-experimental study using repeated cross-sectional data. Setting Behavioral Risk Factor Surveillance System (BRFSS). Sample Pooled data for US adults ages ≥26 years (n = 1,107,673) from BRFSS (2018-2021). Measures States/territories were classified into three levels of stay-at-home order: none, advisory/only for persons at risk, or mandatory for all. Individual-level sociodemographic characteristics were self-reported. Analysis The difference-in-differences method was conducted with weighted multiple logistic regression analysis to examine obesity (body mass index ≥30 kg/m 2 ) prevalence by stay-at-home order level and sociodemographic characteristics before/after the COVID-19 pandemic (January 2018-February 2020 vs March 2020-February 2022). Results After adjusting for a secular trend and multiple covariates, adults in states/territories with mandatory stay-at-home orders experienced a larger increase in obesity prevalence (adjusted odds ratio: 1.05; 95% confidence interval: 1.01, 1.11) than adults in states/territories with no stay-at-home order. Younger adults (vs ≥65 years) and individuals with <high school education (vs ≥4-year college) experienced larger increases in obesity prevalence. Conclusion Increases in obesity prevalence were perpetuated 2 years after implementation of stay-at-home orders, indicating that longer-term health implications are co-occurring during the pandemic recovery period. Future research should focus on successful methods for staying active and healthy during social distancing and beyond.
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Lenz, Heinz‐Josef , Lee, Michael Sangmin, Sohal, Davendra , Safyan, Rachael A. , Zhu, Mojun , Jones, Jeremy , Bhansali, Aditya, Kalwar, Roza, Cho, May , Jones, Jeremy C , Somasundaram, Ashwin , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: TPS228-TPS228

10.1200/jco.2024.42.3_suppl.tps228 Get It

TPS228 Background: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of cancer-related mortality worldwide. PD-1/PD-L1 inhibition, in combination with other modalities, has demonstrated significant benefit in patients (pts) with microsatellite instability-high or mismatch repair–deficient CRC. However, these agents have limited, if any, clinical benefit in pts with microsatellite stable (MSS) or mismatch repair–proficient (pMMR) CRC. RP2 is an enhanced potency oncolytic herpes simplex virus type 1 which expresses the fusogenic gibbon ape leukemia virus glycoprotein with the R sequence deleted (GALV-GP-R–), granulocyte-macrophage colony-stimulating factor (GM-CSF), and an anti–CTLA-4 antibody-like molecule; RP3 additionally expresses 4-1BB and CD40 activating ligands but does not express GM-CSF. Both agents have demonstrated preliminary safety and antitumor activity in pts with solid tumors. This study will evaluate the safety and activity of RP2 and RP3 in combination with atezolizumab (Atezo) plus bevacizumab (Bev) in pts with advanced MSS/pMMR CRC (NCT05733611). Methods: Pts with a histologic diagnosis of unresectable and/or metastatic CRC, with documented MSS or pMMR status, and previously treated with up to 3 standard-of-care systemic regimens will be enrolled in the RP2 + Atezo + Bev or RP3 + Atezo + Bev treatment groups (30 pts per group). Further key inclusion criteria include Eastern Cooperative Oncology Group performance status 0 to 1 and adequate hepatic, renal, and hematologic function. RP2/RP3 will be injected into tumors by direct or image-guided injection. Pts will receive 8 total doses of up to 10 mL of RP2 or RP3, with a first dose concentration of 1 × 106 plaque-forming units (PFU)/mL, followed by 3 doses of 1 × 107 PFU/mL every 2 weeks, and then 4 doses of 1 × 107 PFU/mL every 3 weeks. Pts may receive a second course of up to 8 injections of RP2/RP3 if study criteria are met. Bev will be administered starting on week 1; Atezo will be administered starting week 7. The primary endpoint is objective response rate; secondary endpoints are safety, overall survival, progression-free survival, duration of response, and complete response rate. Antitumor activity will be evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 as modified for this study. Safety will be assessed by physical examination, clinical laboratory evaluations, vital signs, and monitoring for adverse events (AEs; including serious AEs). Clinical trial information: NCT05733611 .
Patient-targeted education (ePRO-E) to increase ePRO intent within an Alliance clinical trial (A221805-SI1)
Smith, Elizabeth , Hillman, Shauna L., Scott, Mary R , Harlos, Elizabeth, Wills, Rachel, Loprinzi, Charles L. , Zahrieh, David M. , Lavoie Smith, Ellen M , Hillman, Shauna, Cho, Youmin , Wilson, Christina M.

Mayo Clinic

JNCI Cancer Spectrum | January 17, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/jncics/pkae002 | PMID 38230706 Get It

Abstract Background The Patient Cloud ePRO app was adopted by the National Cancer Institute National Clinical Trials Network (NCTN) to facilitate capturing electronic patient-reported (ePRO) outcome data, but use has been low. The study objectives were to test whether a patient-targeted ePRO educational resource (ePRO-E) would increase ePRO intent (number of users) and improve data quality (high quality: ≥80% of the required surveys submitted) within an ongoing NCTN study. Methods The ePRO-E intervention, a patient-targeted educational resource (written material and 6-minute animated YouTube video), was designed to address ePRO barriers. ePRO intent and data quality were compared between 2 groups (N = 69): a historical control group and a prospectively recruited intervention group exposed to ePRO-E. Covariates included technology attitudes, age, sex, education, socioeconomic status, and comorbidity. Results Intervention group ePRO intent (78.8%) was statistically significantly higher than historical control group intent (47.1%) (P = .03). Patients choosing ePRO versus paper surveys had more positive and higher technology attitudes scores (P = .03). The odds of choosing ePRO were 4.7 times higher (95% Confidence Interval [CI] = 1.2 to 17.8) (P = .02) among intervention group patients and 5.2 times higher (95% CI = 1.3 to 21.6) (P = .02) among patients with high technology attitudes scores, after controlling for covariates. However, the 80% submission rate (percentage submitting ≥80% of required surveys) in the ePRO group (30.6%) was statistically significantly lower than in the paper group (57.9%) (P = .05). Conclusions ePRO-E exposure increased ePRO intent. High technology attitudes scores were associated with ePRO selection. Since the ePRO survey submission rate was low, additional strategies are needed to promote high-quality data submission.
Utilizing patient-derived induced pluripotent stem cells to investigate GNE myopathy (2156)
Schmitt, R. , Smith, Douglas H. , Cho, Dong Seong , Milone, Margherita , Doles, Jason D.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2156 Get It

Inter-institutional analysis of the outcome after postcardiotomy veno-arterial extracorporeal membrane oxygenation
Biancari, Fausto , Mäkikallio, Timo , Loforte, Antonio , Kang, Jin Kook, Welp, Henryk , Jónsson, Kristján , Pérez, Francisco José Hernández, Alkhamees, Khalid , Fiore, Antonio , Spadaccio, Cristiano , Pettinari, Matteo , Perrotti, Andréa , L’Acqua, Camilla , AlBarak, Mohammed M, Laimoud, Mohamed , Samalavičius, Robertas , Jankuvienė, Agnė, Alonso-Fernández-Gatta, Marta , Wilhelm, Markus J. , Juvonen, Tatu, Sahli, Sebastian D , L'Acqua, Camilla , Arafat, Amr A , Laimoud, Mohamed , Samalavicius, Robertas , Jónsson, Kristján , Loforte, Antonio , Pettinari, Matteo , Fiore, Antonio , Alonso-Fernandez-Gatta, Marta , Kaserer, Alexander , Ruggieri, Vito Giovanni , Cho, Sung‐Min , Kang, Jin Kook , Dalén, Magnus , Ragnarsson, Sigurður , Gatti, Giuseppe , Lechiancole, Andrea , Rosato, Stefano , Sahli, Sebastian D. , Albabtain, Monirah Abdulrahman , Djordjevic, Ilija , Krasivskyi, Ihor , Mariscalco, Giovanni

Mayo Clinic

The International Journal of Artificial Organs | December 5, 2023 | Volume: 47 | Issue: 1 | Pages: 25-34

10.1177/03913988231214934 | PMID 38053227 Get It

Introduction: Patients requiring postcardiotomy veno-arterial extracorporeal membrane oxygenation (V-A-ECMO) have a high risk of early mortality. In this analysis, we evaluated whether any interinstitutional difference exists in the results of postcardiotomy V-A-ECMO. Methods: Studies on postcardiotomy V-A-ECMO were identified through a systematic review for individual patient data (IPD) meta-analysis. Analysis of interinstitutional results was performed using direct standardization, estimation of observed/expected in-hospital mortality ratio and propensity score matching. Results: Systematic review of the literature yielded 31 studies. Data from 10 studies on 1269 patients treated at 25 hospitals were available for the present analysis. In-hospital mortality was 66.7%. The relative risk of in-hospital mortality was significantly higher in six hospitals. Observed versus expected in-hospital mortality ratio showed that four hospitals were outliers with significantly increased mortality rates, and one hospital had significantly lower in-hospital mortality rate. Participating hospitals were classified as underperforming and overperforming hospitals if their observed/expected in-hospital mortality was higher or lower than 1.0, respectively. Among 395 propensity score matched pairs, the overperforming hospitals had significantly lower in-hospital mortality (60.3% vs 71.4%, p = 0.001) than underperforming hospitals. Low annual volume of postcardiotomy V-A-ECMO tended to be predictive of poor outcome only when adjusted for patients’ risk profile. Conclusions: In-hospital mortality after postcardiotomy V-A-ECMO differed significantly between participating hospitals. These findings suggest that in many centers there is room for improvement of the results of postcardiotomy V-A-ECMO.
AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Henderson, Tara O. , Keller, Frank G. , Pei, Qinglin , Wu, Yue , Milgrom, Sarah A. , Roth, Lisa , Cho, Steve , LaCasce, Ann S. , Allen, Pamela B. , Evens, Andrew M. , Kelly, Kara M. , Evens, Andrew M , Hu, Boyu , Hoppe, Bradford S. , Yao, Song , Khan, Niloufer , Vega, Raymond B. Mailhot , Parsons, Susan K. , Kahn, Justine M , DuVall, Adam , Hinds, Pamela S. , Grover, Natalie S. , Schöder, Heiko , Castellino, Sharon M.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3084-3084

10.1182/blood-2023-189652 Get It

Background: Chemotherapy in combination with radiotherapy (RT) is the standard for early-stage (ES) Hodgkin lymphoma (cHL). Despite high cure rates (12-year overall survival (OS) &gt;93%), there is room to improve short and long-term outcomes for children and adults with ES cHL. Incorporation of immunotherapy (IO) into front line treatment of ES cHL is an opportunity to both improve progression-free survival (PFS) and maintain OS, while minimizing long-term morbidity and mortality by reducing exposure to RT and high-dose chemotherapy. Study Design and Methods: HL leaders of the NCTN groups, expert HL researchers and physicians, and representatives from the Cancer Therapy Evaluation Program (CTEP) formed a working group in April 2020 with the goals of harmonizing treatment approaches for ES cHL across pediatric and adult patients and reaching consensus regarding the optimal study design for incorporating IO therapy into frontline treatment. Study champions identified from each of the North American cooperative groups [Children's Oncology Group (COG), SWOG, ECOG-ACRIN, Alliance, NRG] and experts in imaging, radiation oncology, lymphoma biology and patient-reported outcomes (PROs) were included. The resulting COG-led clinical trial, AHOD2131, represents the largest ES cHL trial in the history of North American cooperative groups and the first to enroll patients across the age continuum. AHOD2131 (NCT05675410; Figure) is a randomized, phase 3 trial enrolling patients ages 5 to 60 years with newly diagnosed, previously untreated stage I and II cHL and will investigate the addition of the CD30-antibody drug conjugate brentuximab vedotin (Bv) with PD-1 blockade (nivolumab) compared to standard chemotherapy +/- RT. Since the April 2023 activation, 97 North American sites have activated the trial, and 21 participants have enrolled. Target enrollment is 1875 patients over 5 years of accrual, for an estimated 1782 eligible and evaluable patients. The primary objective is to compare the 3-year PFS of patients with ES cHL treated through a response-adapted, superiority design with either standard therapy or with an IO approach (BV + nivolumab). All patients will be stratified as favorable or unfavorable based on disease risk features at enrollment. Based on initial response assessment by PET/CT (via central review) after 2 cycles of ABVD, patients were classified to PET2 positive (SER, defined as 5 Point Score 4 or 5, ~15% of patients) and PET negative (RER). Those who are PET positive will receive involved site RT (ISRT). The SER and RER patients will be randomized to standard chemotherapy vs. IO therapy respectively. In addition to the primary outcome of PFS, there are 11 secondary and 10 exploratory aims. The secondary aims focus on OS, PFS of subgroups, and event-free survival at 12 years, physician-reported treatment-related adverse event (AE) rates, patient-reported AE using pediatric and adult versions of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and the capture of representation by self-report and the use of electronic PRO data collections. The exploratory aims include the assessment of imaging central review as compared to local institutional review and the use of convolutional neural networks through artificial-intelligence machine learning. The study will examine the effect of therapy on acute and long-term adverse effects including health-related quality of life (HRQoL) and OS for up to 12 years. The study will compare patient self-report and provider AE reports and evaluate the associations of self-reported race/ethnicity and social determinants of health (SDOH)and post-progression/post-relapse OS. AHOD2131 strengthens the effort between the North American cooperative groups to conduct collaborative clinical trials and aims to harmonize an improved standard of care for ES cHL across the age continuum.
In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma
Karagkouni, Dimitra , Thomas, Beena , Song, Yizhe , Vij, Ravi , D’souza, Darwin , Dawson, Travis , Kelly, Geoffrey , Kumar, Shaji , Avigan, David , Ding, Li , Kourelis, Taxiarchis , Lepisto, Eva M. , Cook, April , Hamilton, Mark , Mulligan, George, Network, Immune, Vlachos, Ioannis S. , Gnjatic, Sacha , Gnjatic, Sacha , Song, Yizhe , Vlachos, Ioannis S , Pita-Juárez, Yered , Gonzalez‐Kozlova, Edgar , Ma, Yuling , Yao, Lijun , Pilcher, William , Thomas, Beena, Lagana, Alessandro , Satpathy, Sarthak , Bhasin, Swati S. , Schulman, Jessica , Kim-Schulze, Seunghee , Cho, Hearn Jay , Bhasin, Manoj K , Cook, April

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 648-648

10.1182/blood-2023-189940 Get It

Introduction Newly-diagnosed multiple myeloma (MM) patients often share tumor genetic abnormalities associated with a high risk of progression and poor survival. We hypothesized that single-cell transcriptomic characterization of the tumor immune microenvironment (TIME) may be combined with tumor-based risk stratification to uncover novel disease biology mechanisms associated with clinical outcomes and improve risk stratification. Methods We performed single-cell RNA sequencing of 361 CD138 negative sorted bone marrow mononuclear cells (BMMCs) samples from 263 MM patients enrolled at time of diagnosis in the Multiple Myeloma Research Foundation CoMMpass study (NCT01454297). Specimens were analyzed at baseline (n=263) across a network of five collaborating academic research centers following assay harmonization. Genetic factors that determine risk were defined as one or more of the following gain- or loss-of-function events derived from baseline genomic sequencing data: del17p14, translocations of the Ig locus with the MAF/A/B or WHSC1/MMSET/NSD2 loci, and gain of chromosome 1q21. Statistical modeling strategies were used to assess single-cell populations or RNA signatures associations with known risk factors or disease progression (FDR&lt;0.05). Results The study generated high-quality single-cell profiles of 731,643 cells from 123 high-risk and 107 standard-risk MM patients based on genetics. Based on distinct transcriptome profiles, BMMCs formed 106 clusters corresponding to 5 major compartments: NK and T cells, B cells, erythrocytes, myeloid cells, and plasma cells. Our preliminary differential abundance analysis comparing high- vs standard-risk patients at baseline uncovered significant differences in the TIME associated with genetic risk. The high-risk group was identified as enriched in effector CD8+, and CD4+ T cells. In contrast, the high-risk group exhibited depletion of naive CD8+ and interferon-associated CD4+ and CD8+ T as compared to the standard-risk group. Within subclusters in the T and NK cells compartment, a higher cytotoxicity signature was observed in high-risk patients, characterized by the expression of granzymes and perforin. Finally, our preliminary survival and progression analysis associated a higher frequency of IDO1-expressing macrophages in worst progression patients, while better outcomes were associated with CD8+ T and B cells expressing androgen response and IL6/STAT3/EMT programs, respectively. Conclusions Current approaches for risk stratification are based on bulk measurements of tumor's genetic or epigenetics features, which do not capture the diversity and dynamics of the TIME. Through single-cell transcriptomics, we were able to capture, in high granularity, the TIME and correlate specific immune cell populations and phenotypes with relapse risk and poor prognostic outcomes. These results suggest that immune subpopulations may be an essential novel aspect for improving current risk stratification models.
Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3
Zonder, Jeffrey A. , Vij, Ravi , Pianko, Matthew J. , Hultcrantz, Malin , Wozniak, Katie, Martillo, Mercedes , Kumar, Shaji , Richter, Joshua , Nathwani, Nitya , Bianchi, Giada , Hofmeister, Craig C. , Kaur, Gurbakhash , Cho, Hearn Jay

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3387-3387

10.1182/blood-2023-184949 Get It

Background: Multiple myeloma (MM) is characterized by somatic mutations involving cancer-associated genes. The MyDRUG trial was initiated to explore the efficacy of specific molecularly-targeted therapies in combination with a standard triplet combination in MM. Methods: MyDRUG (NCT03732703) is a genomically-guided umbrella trial for patients with functional high-risk MM, defined as early relapse following primary therapy (3 years for transplant with maintenance, 18 months without), with specific genetic abnormalities. Patients with no actionable mutation or mutations with allelic burden below 30% were randomly assigned to one of the “non-actionable” arms. Here we present the data for the Y3 arm which combines selinexor (60mg po days 1,8,15), ixazomib (4mg po days 1,8,15), pomalidomide (3mg po days 1-21) and dexamethasone (40mg po weekly) (Seli-IPD), given on a 28-day cycle. The primary objective of the Y3 sub-protocol was to evaluate the overall response rate (ORR) according to the International Myeloma Working Group consensus criteria. Secondary objectives included assessment of adverse events (AEs). Results: 17 patients were enrolled into the Y3 arm. The average age was 62 (51-79), 65% were male with a median of 29 months since initial diagnosis and a median of 2 prior lines of therapy. The ORR (&gt; PR) was 52.9% with a clinical benefit rate (&gt; MR) of 58.8%. The median progression free survival was 10.2 months ( 95% CI: 3.9; 12.9) with a median overall survival which has not yet been reached; with all 17 patients still alive at the current data cutoff. No dose-limiting toxicities were seen. Eight patients (47.1%) experienced a serious AE with 2 patients (11.8%) experiencing an AE leading to treatment discontinuation. Two patients (11.8%) required dose reductions. The most common non-hematologic AEs were fatigue, nausea and constipation; all of which were grade 1 and 2. Conclusions: In this platform study of patients with relapsed, functionally high-risk MM, patients who received Seli-IPd exhibited significant efficacy and a manageable AE profile. Furthermore, this provides an all-oral option for patients wishing to minimize their office visits and parenteral therapy administrations.
Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
Novelli, Silvana , Poon, Michelle, Yi, Shuhua , Guidez, Stéphanie , Jagadeesh, Deepa, Zhang, Wei , Tani, Monica , Cai, Jessica, Uppala, Amulya , Shariff, Saleem, Chi, Lei, Chaudhry, Aafia, Ambati, Srikanth, Villasboas, José C. , Kim, Tae Min , Taszner, Michał , Cho, Seok‐Goo , Merli, Michele , Ubieto, Ana Jiménez , Tessoulin, Benoit , Walewski, Jan , Song, Yuqin , Chong, Geoffrey , Luminari, Stefano , Bachy, Emmanuel , Alonso, Aránzazu , Jagadeesh, Deepa , Magnano, Laura , Iskierka‐Jazdzewska, Elżbieta , Mohamed, Hesham , Tucker, David

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3041-3041

10.1182/blood-2023-181650 Get It

Background The class of CD20×CD3 bispecific antibodies (BsAbs) has emerged as an important anti-lymphoma modality for patients (pts) with R/R B-cell non-Hodgkin lymphoma. Odronextamab, a novel, off-the-shelf, CD20×CD3 BsAb, has previously demonstrated compelling efficacy in both R/R diffuse large B-cell lymphoma and R/R FL. In pts with R/R FL, odronextamab monotherapy achieved 75% complete response (CR) rates and encouraging durability of responses, and showed generally manageable safety, in the Phase 2 ELM-2 study (NCT03888105; Kim TM, et al. ASH. 2022). Here, we report the results of a second, pre-specified interim analysis of ELM-2. Methods Intravenous odronextamab was administered weekly in 21-day cycles during Cycles (C) 1-4. Optimization of the step-up regimen to further mitigate cytokine release syndrome (CRS) was reported previously (Kim TM, et al. ASH. 2022). Odronextamab was administered with steroid prophylaxis and step-up doses of 0.7/4/20 mg during C1, followed by 80 mg on Days 1, 8, and 15 of C2-4. After C4, odronextamab maintenance treatment continued at 160 mg every 2 weeks until disease progression or unacceptable toxicity. Pts who achieved a durable CR for ≥9 months transitioned to dosing every 4 weeks. A pre-specified interim analysis was performed when 80 pts had completed ≥12 months follow-up. The primary endpoint was objective response rate (ORR), assessed by independent central review (ICR) according to the Lugano classification. Key secondary endpoints included CR rate, duration of response (DoR), progression-free survival (PFS), overall survival (OS), and changes in scores of patient-reported outcomes. Minimal residual disease (MRD) was included as an exploratory endpoint. Results At data cut off (Jan 31, 2023), the global study was fully enrolled and included 140 safety-evaluable pts with FL; 128 pts were efficacy-evaluable and 85 pts had ≥12 months follow-up. The median duration of study follow-up for efficacy was 26.6 months. In the safety-evaluable FL population, median age was 60.5 years (range 22-84), 53% were male, and pts had received a median of 3 (range 2-13) prior lines of therapy. 73% of pts were refractory to their last therapy, 41% were double refractory, and 74% were refractory to an anti-CD20 antibody. 50% of pts had progression of disease within 2 years (POD24) and 29% had a prior autologous hematopoietic stem cell transplant. ORR and CR rate by ICR were 80% (102/128) and 72% (92/128), respectively, and were consistent across pts with high-risk features. Responses were durable, with both median DoR and duration of CR of 21.7 months; the probability of maintaining CR for 24 months was 48%. Median PFS was 20.7 months (95% CI: 16.7-26.5) and median OS was not reached; the probability of survival at 3 years was 63%. Patient-reported overall quality of life (QoL) scores were maintained during the course of treatment. MRD status at 12 weeks was highly predictive of PFS. Safety was generally consistent with previous reports, and no new treatment-related Grade (Gr) 5 events were recorded since the first interim analysis. The most common treatment-emergent AEs (&gt;30% all grades) were CRS (55%), anemia (34%), neutropenia (34%), and pyrexia (33%). With the optimized 0.7/4/20 mg step-up regimen (n=72), 98% of CRS events were Gr 1/2, and only one pt had Gr 3 CRS. All CRS events resolved with supportive measures; 13 pts received tocilizumab for CRS management with the optimized regimen. Only one low-grade ICANS event was reported with the optimized regimen. Gr ≥3 infections occurred in 50 (36%) pts (Gr 5, n=14 [10%]); COVID-19 infections were reported in 46 (35%) pts (Gr 5, n=8 [6%]). Conclusions The results of this pre-specified analysis of the Phase 2 ELM-2 study continue to demonstrate deep and durable responses with odronextamab in heavily pretreated, refractory pts with R/R FL. 90% of responders were complete responders, with a 48% probability of maintaining CR for 2 years. High CR rates appear to translate to favorable, long-term survival outcomes in the setting of incurable disease. The incidence of AEs was consistent with earlier reports, with no new treatment-related Gr 5 events. Importantly, continued treatment with odronextamab had no detrimental effects on overall QoL. These data underscore the promise of odronextamab as a potentially effective agent for the management of R/R FL. Updated data will be presented.
Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma
Novelli, Silvana , Poon, Michelle, Yi, Shuhua , Guidez, Stéphanie , Jagadeesh, Deepa, Zhang, Wei , Tani, Monica , Cai, Jessica, Ivanescu, Cristina, Chaudhry, Aafia, Ambati, Srikanth, Chi, Lei, Tessoulin, Benoit , Cho, Seok‐Goo , Taszner, Michał , Kim, Tae Min , Villasboas, José C. , Merli, Michele , Ubieto, Ana Jiménez , Tucker, David , Walewski, Jan , Song, Yuqin , Chong, Geoffrey , Bachy, Emmanuel , Alonso, Aránzazu , Jagadeesh, Deepa , Magnano, Laura , Iskierka‐Jazdzewska, Elżbieta , Reaney, Matthew D. , Mohamed, Hesham , Harnett, James , Luminari, Stefano

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 669-669

10.1182/blood-2023-181942 Get It

Background: Goals of patient-centered care for management of relapsed or refractory follicular lymphoma (R/R FL) are to improve clinical outcomes while maintaining or improving health-related quality of life (HRQoL). In ELM-2 (NCT03888105), a Phase 2, open-label, multicohort, multicenter study, odronextamab monotherapy demonstrated high and durable complete response rates and generally manageable safety in patients with R/R FL. We report here, for the first time, patient-reported outcome (PRO) results from ELM-2 in patients with R/R FL. Methods: Patients with R/R FL Grade 1-3a received odronextamab IV at 80 mg weekly in 21-day cycles in Cycles (C) 1-4. Optimization of the step-up regimen to mitigate cytokine release syndrome (CRS) was reported previously. Odronextamab was administered with steroid prophylaxis and step-up doses of 0.7/4/20 mg in C1, then 80 mg on Days 1, 8, and 15 of C2-4. After C4, odronextamab maintenance continued at 160 mg every 2 weeks until disease progression or unacceptable toxicity. Patients with durable complete response (≥9 months) switched to dosing every 4 weeks. Patients completed EORTC QLQ-C30, FACT-Lym, and EQ-5D-3L questionnaires at Weeks 1 (baseline), 2, 3, 4, and 10, then every 8 weeks for the remainder of the first year and every 12 weeks in the second year. Results here focus on six key PRO scales: EORTC QLQ-C30 Global Health Status/Quality of Life (GHS/QOL), physical functioning (PF), role functioning (RF), and fatigue; FACT-Lym lymphoma subscale (LymS); and EQ-5D-3L visual analog score (VAS). Longitudinal analyses using mixed models for repeated measures (MMRM) were conducted through Week 50 (the last visit with ≥10 patients with PRO data). Changes from baseline were considered statistically significant if the 95% confidence interval did not contain zero. No adjustment for multiplicity was performed, hence all statistical significance is nominal. Published ranges for minimum important difference (MID) to define clinically meaningful changes are: EORTC QLQ-C30 scales, 10 points; FACT-Lym LymS, 2.9-5.4 points; and EQ-5D-3L VAS, 7-12 points. For responder and time to definitive deterioration (TTDD) analyses, the upper end of these published MID ranges was used to define deterioration or improvement. Results: At the ELM-2 interim data cutoff on 31-Jan-2023, 140 patients with R/R FL Grade 1-3a had received at least 1 dose of odronextamab. Median age was 60.5 years (range: 22-84), with 38.6% ≥65 years, 52.9% male, 57.1% White, 32.1% Asian, 52.2% ECOG=0, and 47.1% ECOG=1. Median duration of follow-up was 26.6 months (range: 6.2-37.5). PRO completion rates for EORTC-QLQ-C30, FACT-Lym, and EQ-5D-3L were high at baseline and remained high for all assessments through Week 50. At baseline, moderate levels of general health (GHS/QoL) and high levels of functioning (PF and RF) were observed that were higher (better) than reference values for general cancer or non-Hodgkin's Lymphoma (NHL). Fatigue scores at baseline were lower (less symptoms) than reference values for general cancer or NHL. EORTC QLQ-C30 GHS/QOL, PF, RF, and fatigue scores were maintained from baseline through Week 50 (Table). For EQ-5D-3L VAS, the overall estimated mean changes from baseline improved statistically significantly but did not reach MID thresholds (Table). For FACT-Lym LymS, overall estimated mean change from baseline statistically significantly improved, and scores improved statistically significantly from Weeks 10 to 42 (except Week 34), with clinically meaningful improvements at Weeks 26 and 42 (Figure). The proportion of patients reporting meaningful improvement or stability across the six scales was higher than the proportion reporting meaningful worsening through Week 50 (Table). The median TTDD for EORTC-QLQ-C30 GHS/QoL was 22.41 (95% CI: 14.59 to not yet reached) months, corresponding to the median PFS. Median TTDD was not reached for EORTC QLQ-C30 PF, FACT-Lym LymS, and EQ-5D-3L VAS scales. Conclusions: For patients with R/R FL, patient-reported HRQoL results were favorable during odronextamab treatment until disease progression, with no detriments on patient-reported symptoms, functioning, and overall quality of life. These results complement encouraging clinical efficacy, durability of responses, and tolerability observed in this highly refractory patient population and support the future role of odronextamab in the management of patients with R/R FL.